Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Allan C deCamp"'
Autor:
Bryan T Mayer, Allan C deCamp, Yunda Huang, Joshua T Schiffer, Raphael Gottardo, Peter B Gilbert, Daniel B Reeves
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 4, p e1010003 (2022)
Broadly neutralizing antibodies (bNAbs) are promising agents to prevent HIV infection and achieve HIV remission without antiretroviral therapy (ART). As with ART, bNAb combinations are likely needed to cover HIV's extensive diversity. Not all bNAbs a
Externí odkaz:
https://doaj.org/article/b20d108e19284c90906534360439205e
Autor:
Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Sarita Naidoo, Mina C Hosseinipour, Craig Innes, Linda-Gail Bekker, Nicole Grunenberg, Philipp Mann, Chenchen Yu, Allan C deCamp, Maurine D Miner, Nicole L Yates, Jack Heptinstall, Nonhlanhla N Mkhize, One Dintwe, Nicole Frahm, Kristen W Cohen, Mary Allen, Julia Hutter, Ralf Wagner, Giuseppe Pantaleo, M Juliana McElrath, Georgia D Tomaras, Lynn Morris, David C Montefiori, Erica Andersen-Nissen, Glenda E Gray, Peter B Gilbert, James G Kublin, NIAID HVTN 100 and HVTN 111 trial teams
Publikováno v:
PLoS Medicine, Vol 17, Iss 5, p e1003117 (2020)
BackgroundDNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with ha
Externí odkaz:
https://doaj.org/article/7c285a3459774f30806f3e5507798d93
Autor:
Yehuda Z Cohen, Allison L Butler, Katrina Millard, Maggi Witmer-Pack, Rebeka Levin, Cecilia Unson-O'Brien, Roshni Patel, Irina Shimeliovich, Julio C C Lorenzi, Jill Horowitz, Stephen R Walsh, Shu Lin, Joshua A Weiner, Anna Tse, Alicia Sato, Chelsey Bennett, Bryan Mayer, Kelly E Seaton, Nicole L Yates, Lindsey R Baden, Allan C deCamp, Margaret E Ackerman, Michael S Seaman, Georgia D Tomaras, Michel C Nussenzweig, Marina Caskey
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0219142 (2019)
BackgroundAdditional forms of pre-exposure prophylaxis are needed to prevent HIV-1 infection. 3BNC117 and 10-1074 are broadly neutralizing anti-HIV-1 antibodies that target non-overlapping epitopes on the HIV-1 envelope. We investigated the safety, t
Externí odkaz:
https://doaj.org/article/b4f6a55fa3004a4ca5d76ce1d1d48b8b
Autor:
Lautaro G Perez, David R Martinez, Allan C deCamp, Abraham Pinter, Phillip W Berman, Donald Francis, Faruk Sinangil, Carter Lee, Kelli Greene, Hongmei Gao, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Robert J O'Connell, Merlin L Robb, Nelson L Michael, Jerome H Kim, Peter Gilbert, David C Montefiori
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0180720 (2017)
Non-neutralizing IgG to the V1V2 loop of HIV-1 gp120 correlates with a decreased risk of HIV-1 infection but the mechanism of protection remains unknown. This V1V2 IgG correlate was identified in RV144 Thai trial vaccine recipients, who were primed w
Externí odkaz:
https://doaj.org/article/c36ea6f861184e5d9675e59626f76437
Autor:
Mohammed S Aiyegbo, Evgeny Shmelkov, Lorenzo Dominguez, Michael Goger, Shibani Battacharya, Allan C deCamp, Peter B Gilbert, Phillip W Berman, Timothy Cardozo
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170530 (2017)
The only evidence of vaccine-induced protection from HIV acquisition in humans was obtained in the RV144 HIV vaccine clinical trial. One immune correlate of risk in RV144 was observed to be higher titers of vaccine-induced antibodies (Abs) reacting w
Externí odkaz:
https://doaj.org/article/abd1b8611f2343b59eeba8e06791008e
Autor:
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, Eric Sanders-Buell, Breana Hall, Craig A Magaret, Andrew J Fiore-Gartland, Michal Juraska, Lindsay N Carpp, Shelly T Karuna, Meera Bose, Steven LePore, Shana Miller, Annemarie O'Sullivan, Kultida Poltavee, Hongjun Bai, Kalpana Dommaraju, Hong Zhao, Kim Wong, Lennie Chen, Hasan Ahmed, Derrick Goodman, Matthew Z Tay, Raphael Gottardo, Richard A Koup, Robert Bailer, John R Mascola, Barney S Graham, Mario Roederer, Robert J O'Connell, Nelson L Michael, Merlin L Robb, Elizabeth Adams, Patricia D'Souza, James Kublin, Lawrence Corey, Daniel E Geraghty, Nicole Frahm, Georgia D Tomaras, M Juliana McElrath, Lisa Frenkel, Sheila Styrchak, Sodsai Tovanabutra, Magdalena E Sobieszczyk, Scott M Hammer, Jerome H Kim, James I Mullins, Peter B Gilbert
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0185959 (2017)
Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall efficacy, analysis of breakthrough HIV-1 sequences in participants can help determine whether vaccine-induced immune responses impacted viruses that
Externí odkaz:
https://doaj.org/article/a98b506eef10499fa4bd6e7bb5f122ff
Autor:
Allan C. deCamp, Martin M. Corcoran, William J. Fulp, Jordan R. Willis, Christopher A. Cottrell, Daniel L. V. Bader, Oleksandr Kalyuzhniy, David J. Leggat, Kristen W. Cohen, Ollivier Hyrien, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Farhad Rahaman, Angela Lombardo, Vincent Philiponis, Rachael E. Whaley, Aaron Seese, Joshua Brand, Alexis M. Ruppel, Wesley Hoyland, Celia R. Mahoney, Alberto Cagigi, Alison Taylor, David M. Brown, David R. Ambrozak, Troy Sincomb, Tina-Marie Mullen, Janine Maenza, Orpheus Kolokythas, Nadia Khati, Jeffrey Bethony, Mario Roederer, David Diemert, Richard A. Koup, Dagna S. Laufer, Juliana M. McElrath, Adrian B. McDermott, Gunilla B. Karlsson Hedestam, William R. Schief
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targ
Externí odkaz:
https://doaj.org/article/2e580eabca0b4c0f8e97acb243086a89
Autor:
Craig A. Magaret, Li Li, Allan C. deCamp, Morgane Rolland, Michal Juraska, Brian D. Williamson, James Ludwig, Cindy Molitor, David Benkeser, Alex Luedtke, Brian Simpkins, Fei Heng, Yanqing Sun, Lindsay N. Carpp, Hongjun Bai, Bethany L. Dearlove, Elena E. Giorgi, Mandy Jongeneelen, Boerries Brandenburg, Matthew McCallum, John E. Bowen, David Veesler, Jerald Sadoff, Glenda E. Gray, Sanne Roels, An Vandebosch, Daniel J. Stieh, Mathieu Le Gars, Johan Vingerhoets, Beatriz Grinsztejn, Paul A. Goepfert, Leonardo Paiva de Sousa, Mayara Secco Torres Silva, Martin Casapia, Marcelo H. Losso, Susan J. Little, Aditya Gaur, Linda-Gail Bekker, Nigel Garrett, Carla Truyers, Ilse Van Dromme, Edith Swann, Mary A. Marovich, Dean Follmann, Kathleen M. Neuzil, Lawrence Corey, Alexander L. Greninger, Pavitra Roychoudhury, Ollivier Hyrien, Peter B. Gilbert
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-22 (2024)
Abstract In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 v
Externí odkaz:
https://doaj.org/article/ae82624b40e944a5925f8f3c70ded9b7
Autor:
Paul T Edlefsen, Morgane Rolland, Tomer Hertz, Sodsai Tovanabutra, Andrew J Gartland, Allan C deCamp, Craig A Magaret, Hasan Ahmed, Raphael Gottardo, Michal Juraska, Connor McCoy, Brendan B Larsen, Eric Sanders-Buell, Chris Carrico, Sergey Menis, Gustavo H Kijak, Meera Bose, RV144 Sequencing Team, Miguel A Arroyo, Robert J O'Connell, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Supachai Rerks-Ngarm, Merlin L Robb, Tatsiana Kirys, Ivelin S Georgiev, Peter D Kwong, Konrad Scheffler, Sergei L Kosakovsky Pond, Jonathan M Carlson, Nelson L Michael, William R Schief, James I Mullins, Jerome H Kim, Peter B Gilbert
Publikováno v:
PLoS Computational Biology, Vol 11, Iss 2, p e1003973 (2015)
The RV144 clinical trial showed the partial efficacy of a vaccine regimen with an estimated vaccine efficacy (VE) of 31% for protecting low-risk Thai volunteers against acquisition of HIV-1. The impact of vaccine-induced immune responses can be inves
Externí odkaz:
https://doaj.org/article/3c48e8cc0f7048819758a015ac56625a
Autor:
Susan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, Nicos Karasavvas, Raphael Gottardo, Constance Williams, Daryl E Morris, Georgia Tomaras, Mangala Rao, Erik Billings, Phillip Berman, Xiaoying Shen, Charla Andrews, Robert J O'Connell, Viseth Ngauy, Sorachai Nitayaphan, Mark de Souza, Bette Korber, Richard Koup, Robert T Bailer, John R Mascola, Abraham Pinter, David Montefiori, Barton F Haynes, Merlin L Robb, Supachai Rerks-Ngarm, Nelson L Michael, Peter B Gilbert, Jerome H Kim
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53629 (2013)
The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients we
Externí odkaz:
https://doaj.org/article/3f8bd381cf2f4c4e9cbc7c43ba28e406